Our Products

Afatinib Tablets 40 mg is a targeted therapy used to treat non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR), particularly in patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations. It is also used for other cancers with similar EGFR mutations. Afatinib is a tyrosine kinase inhibitor that works by blocking the activity of EGFR and other related receptors involved in cancer cell growth, which helps to slow or stop cancer cell proliferation.

The 40 mg dosage is typically taken once daily, with or without food, as prescribed by a healthcare provider. Common side effects include diarrhea, skin rash, mouth sores, fatigue, and liver enzyme changes. Regular monitoring of liver function, as well as managing gastrointestinal and dermatologic symptoms, is important to ensure the effectiveness of the treatment and minimize side effects. Adjustments to the dose may be needed depending on the patient’s tolerance and response to treatment.